Lansoprazole/Amoxicillin/Clarithromycin — Competitive Intelligence Brief

Lansoprazole/Amoxicillin/Clarithromycin (Lansoprazole/Amoxicillin/Clarithromycin) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Proton pump inhibitor + antibiotic combination. Area: Gastroenterology / Infectious Disease.

marketed Proton pump inhibitor + antibiotic combination H+ ATPase (lansoprazole); bacterial cell wall (amoxicillin); bacterial ribosome (clarithromycin) Gastroenterology / Infectious Disease Small molecule

Target snapshot

Lansoprazole/Amoxicillin/Clarithromycin (Lansoprazole/Amoxicillin/Clarithromycin) — HK inno.N Corporation. This triple-therapy combination eradicates Helicobacter pylori by suppressing gastric acid while simultaneously disrupting bacterial cell wall and protein synthesis.

Comparator set (5 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lansoprazole/Amoxicillin/Clarithromycin TARGET	Lansoprazole/Amoxicillin/Clarithromycin	HK inno.N Corporation	marketed	Proton pump inhibitor + antibiotic combination	H+ ATPase (lansoprazole); bacterial cell wall (amoxicillin); bacterial ribosome (clarithromycin)
Omeprazole, Amoxicillin, Metronidazole and Clarithromycin	Omeprazole, Amoxicillin, Metronidazole and Clarithromycin	Al-Azhar University	marketed	Proton pump inhibitor + antibiotic combination therapy	H+ ATPase (omeprazole); bacterial ribosome and cell wall (amoxicillin, clarithromycin); bacterial DNA (metronidazole)
Lansoprzole+Amoxicillin+Clarithromycin	Lansoprzole+Amoxicillin+Clarithromycin	Korean College of Helicobacter and Upper Gastrointestinal Research	marketed	Proton pump inhibitor + antibiotic combination (triple therapy)	H+ ATPase (lansoprazole); bacterial cell wall and protein synthesis (amoxicillin and clarithromycin)
Rabeprazole, metronidazole, Clarithromycin, Amoxicillin	Rabeprazole, metronidazole, Clarithromycin, Amoxicillin	American University of Beirut Medical Center	marketed	Proton pump inhibitor + antibiotic combination therapy	H+ ATPase (rabeprazole); bacterial ribosome and DNA (metronidazole, clarithromycin); bacterial cell wall (amoxicillin)
Vonoprazan + amoxicillin + clarithromycin	Vonoprazan + amoxicillin + clarithromycin	The Third Xiangya Hospital of Central South University	marketed	Proton pump inhibitor + antibiotic combination	H+ K+-ATPase (vonoprazan); bacterial cell wall and protein synthesis (amoxicillin and clarithromycin)
Pantoprazole 40mg, Amoxicillin and Levofloxacin	Pantoprazole 40mg, Amoxicillin and Levofloxacin	Ain Shams University	phase 3	Proton pump inhibitor + antibiotic combination	H+/K+-ATPase (pantoprazole); bacterial DNA gyrase and topoisomerase IV (levofloxacin); bacterial cell wall (amoxicillin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Proton pump inhibitor + antibiotic combination class)

1. Ain Shams University · 1 drug in this class
2. HK inno.N Corporation · 1 drug in this class
3. The Third Xiangya Hospital of Central South University · 1 drug in this class